SubHero Banner

Trodelvy® (sacituzumab govitecan-hziy) – Expanded indication

April 7, 2021 - Gilead announced the FDA approval of Trodelvy (sacituzumab govitecan-hziy), for the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Download PDF